AU2018317789B2 - Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid and a dicarboxylic acid - Google Patents
Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid and a dicarboxylic acid Download PDFInfo
- Publication number
- AU2018317789B2 AU2018317789B2 AU2018317789A AU2018317789A AU2018317789B2 AU 2018317789 B2 AU2018317789 B2 AU 2018317789B2 AU 2018317789 A AU2018317789 A AU 2018317789A AU 2018317789 A AU2018317789 A AU 2018317789A AU 2018317789 B2 AU2018317789 B2 AU 2018317789B2
- Authority
- AU
- Australia
- Prior art keywords
- acid
- tetrahydrofolic acid
- pharmaceutically acceptable
- cancer
- methylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17186518 | 2017-08-16 | ||
| EP17186518.1 | 2017-08-16 | ||
| PCT/EP2018/072077 WO2019034673A1 (en) | 2017-08-16 | 2018-08-15 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE- (6R) -TETRAHYDROFOLIC ACID AND DICARBOXYLIC ACID |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018317789A1 AU2018317789A1 (en) | 2020-04-02 |
| AU2018317789B2 true AU2018317789B2 (en) | 2023-06-29 |
Family
ID=59699495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018317789A Active AU2018317789B2 (en) | 2017-08-16 | 2018-08-15 | Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid and a dicarboxylic acid |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11337978B2 (enExample) |
| EP (1) | EP3668516B1 (enExample) |
| JP (1) | JP7232815B2 (enExample) |
| KR (1) | KR102753593B1 (enExample) |
| CN (1) | CN110996958B (enExample) |
| AU (1) | AU2018317789B2 (enExample) |
| CA (1) | CA3073127A1 (enExample) |
| DK (1) | DK3668516T3 (enExample) |
| ES (1) | ES2902051T3 (enExample) |
| PT (1) | PT3668516T (enExample) |
| WO (1) | WO2019034673A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4536184A1 (en) | 2022-06-08 | 2025-04-16 | Merck Patent GmbH | Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate |
| WO2023237484A1 (en) * | 2022-06-08 | 2023-12-14 | Merck Patent Gmbh | Compositions comprising disodium 5,10-methylene-(6r)-tetrahydrofolate |
| CN119325374A (zh) * | 2022-06-08 | 2025-01-17 | 默克专利股份有限公司 | 包含5,10-亚甲基-(6r)-四氢叶酸的稳定的冻干物 |
| EP4536186A1 (en) * | 2022-06-08 | 2025-04-16 | Merck Patent GmbH | Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112761A2 (de) * | 2003-06-26 | 2004-12-29 | Merck Eprova Ag | Stabile pharmazeutische zusammensetzungen von 5,10-methylentetrahydrofolat |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0165926B1 (en) | 1983-05-20 | 1990-10-24 | Bengt Gustavsson | A device for transferring a substance |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| CH682664A5 (en) | 1991-10-15 | 1993-10-29 | Eprova Ag | Stable salts of 5,10-methylene tetrahydrofolate. |
| CH684644A5 (de) | 1992-07-13 | 1994-11-15 | Eprova Ag | 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen. |
| US20020103126A1 (en) | 1997-04-18 | 2002-08-01 | Roche Diagnostics Gmbh | Stable pharmaceutical form of administration for peptides, proteins and nucleic acids |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| CH696628A5 (de) | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
| KR20080074201A (ko) * | 2005-12-02 | 2008-08-12 | 어드벤트륵스 파마슈티칼스, 인크. | 5,10 메틸렌테트라히드로폴레이트의 안정한 약학 조성물 |
| AU2012234323A1 (en) | 2011-03-29 | 2013-10-17 | Sanofi | Otamixaban formulations with improved stability |
| JP6235779B2 (ja) | 2012-03-28 | 2017-11-22 | 株式会社コーセー | 葉酸含有組成物及び葉酸の安定化方法 |
| EP2799061A1 (en) | 2013-04-30 | 2014-11-05 | Aprofol AG | Stable high dose pharmaceutical composition containing folates |
| EP2837631A1 (en) | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| CN107812195B (zh) | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
| US10059710B2 (en) * | 2016-02-17 | 2018-08-28 | Merck & Cie | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid |
-
2018
- 2018-08-15 EP EP18752161.2A patent/EP3668516B1/en active Active
- 2018-08-15 CA CA3073127A patent/CA3073127A1/en active Pending
- 2018-08-15 PT PT187521612T patent/PT3668516T/pt unknown
- 2018-08-15 AU AU2018317789A patent/AU2018317789B2/en active Active
- 2018-08-15 DK DK18752161.2T patent/DK3668516T3/da active
- 2018-08-15 WO PCT/EP2018/072077 patent/WO2019034673A1/en not_active Ceased
- 2018-08-15 JP JP2020508004A patent/JP7232815B2/ja active Active
- 2018-08-15 US US16/638,528 patent/US11337978B2/en active Active
- 2018-08-15 CN CN201880052764.1A patent/CN110996958B/zh active Active
- 2018-08-15 ES ES18752161T patent/ES2902051T3/es active Active
- 2018-08-15 KR KR1020207007389A patent/KR102753593B1/ko active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004112761A2 (de) * | 2003-06-26 | 2004-12-29 | Merck Eprova Ag | Stabile pharmazeutische zusammensetzungen von 5,10-methylentetrahydrofolat |
Also Published As
| Publication number | Publication date |
|---|---|
| US11337978B2 (en) | 2022-05-24 |
| ES2902051T3 (es) | 2022-03-24 |
| EP3668516A1 (en) | 2020-06-24 |
| US20200368236A1 (en) | 2020-11-26 |
| AU2018317789A1 (en) | 2020-04-02 |
| CA3073127A1 (en) | 2019-02-21 |
| JP7232815B2 (ja) | 2023-03-03 |
| WO2019034673A1 (en) | 2019-02-21 |
| RU2020110073A3 (enExample) | 2022-01-24 |
| CN110996958B (zh) | 2023-05-12 |
| EP3668516B1 (en) | 2021-09-22 |
| RU2020110073A (ru) | 2021-09-16 |
| PT3668516T (pt) | 2021-12-23 |
| JP2020531415A (ja) | 2020-11-05 |
| DK3668516T3 (da) | 2021-12-13 |
| KR102753593B1 (ko) | 2025-01-10 |
| KR20200041354A (ko) | 2020-04-21 |
| CN110996958A (zh) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2392475T3 (es) | Derivados de piperidina y piperazina para el tratamiento de tumores | |
| US12103930B2 (en) | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | |
| EP2753615B1 (de) | Benzonitrilderivate als kinasehemmer | |
| EP2209777B1 (de) | Thiazolderivate zur behandlung von krebs | |
| US8710058B2 (en) | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | |
| EP2812337B1 (en) | Furo [3, 2 - b]pyridine derivatives as tbk1 and ikk inhibitors | |
| AU2018317789B2 (en) | Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid and a dicarboxylic acid | |
| US9382244B2 (en) | 7-azaindole-2,7-naphthyridine derivative for the treatment of tumours | |
| EP2361250B1 (en) | Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |